San Francisco Bay Area biotech stories.
Thursday, March 10, 2011
Genentech's Lucentis works well in trial — but all eyes on NIH study
The Genentech Inc. eye drug Lucentis performed well in a late-stage study of patients with diabetic macular edema — a treatment that could be rejected in the United Kingdom — but the real insight could come next quarter.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)